Abstrakt
Haarlem's conference in 2014 established principles of incorporation of molecular markers into brain tumor diagnoses and became thus the basis for a revision of the 2007 CNS WHO classification. New WHO classification from 2016 changes the 100-year-old principle of histomorphological classification of brain tumors by incorporating molecular parameters into many diagnostic categories.
In this socalled integrated diagnosis, molecular parameters are assessed in the context of pertinent histologic diagnoses. New entities that are defined by histology and molecular features are: IDH-wildtype and IDH-mutant glioblastoma, H3 K27M-mutant diffuse midline glioma, RELA fusion-positive ependymoma, WNT-activated and SHH-activated medulloblastoma and C19MC-altered embryonal tumor with multilayered rosettes.
The 2016 WHO classification should be mandatory for the brain tumor diagnosis.